Sanctuary Advisors LLC Purchases New Position in Prestige Consumer Healthcare Inc. $PBH

Sanctuary Advisors LLC bought a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 14,407 shares of the company’s stock, valued at approximately $681,000.

Other large investors have also recently bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in shares of Prestige Consumer Healthcare during the second quarter worth about $30,000. Emerald Investment Advisers LLC purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $2,328,000. Callan Family Office LLC purchased a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth $548,000. Heartland Advisors Inc. purchased a new stake in Prestige Consumer Healthcare during the second quarter worth about $360,000. Finally, Keating Financial Advisory Services Inc. purchased a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $145,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

PBH has been the topic of several recent research reports. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group lowered their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Finally, Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $70.75.

More Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Attractive value profile: A Zacks comparison of PBH and Stryker (SYK) highlights the value-investing case for Prestige Consumer Healthcare. PBH’s lower earnings multiple and defensive consumer-healthcare portfolio could support investor interest, although the comparison does not guarantee that PBH is the superior investment. PBH vs. SYK: Which Stock Is the Better Value Option?
• Positive Sentiment: Longer-term earnings growth: Zacks Research projects EPS of $4.55 for fiscal 2027, rising to $5.06 in fiscal 2028 and $5.25 in fiscal 2029. The forecasts imply improving earnings power and provide a potential catalyst if the company delivers.
• Neutral Sentiment: Quarterly estimates remain steady: Zacks forecasts EPS of $1.06 for fiscal Q2 2027, $1.22 for Q3 and $1.30 for Q4, followed by estimates of $1.14, $1.19, $1.38 and $1.35 for fiscal 2028’s quarters. These projections indicate expectations for consistent profitability rather than a near-term earnings surprise.
• Negative Sentiment: Analyst stance is cautious: Zacks Research maintains a “Hold” rating, and its fiscal 2027 EPS forecast of $4.55 is essentially in line with the $4.56 consensus estimate. That suggests the expected earnings growth is largely recognized in current expectations, limiting an immediate upgrade catalyst.

Prestige Consumer Healthcare Trading Up 2.5%

NYSE:PBH opened at $52.48 on Friday. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of 14.70, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The business’s 50-day simple moving average is $50.22 and its 200 day simple moving average is $54.62.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. During the same quarter last year, the firm earned $0.90 EPS. Prestige Consumer Healthcare’s quarterly revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).